Abstract:Chemical manipulation of estrogen receptor alpha ligand binding domain structural mobility tunes receptor lifetime and influences breast cancer therapeutic activities. Selective estrogen receptor modulators (SERMs) extend ERα cellular lifetime/accumulation. They are antagonists in the breast but agonists in the uterine epithelium and/or in bone. Selective estrogen receptor degraders/downregulators (SERDs) reduce ERα cellular lifetime/accumulation and are pure antagonists. Activating somatic ESR1 mutations Y537S and D538G enable resistance to first-line endocrine therapies. SERDs have shown significant activities in ESR1 mutant setting while few SERMs have been studied. To understand whether chemical manipulation of ERα cellular lifetime and accumulation influences antagonistic activity, we studied a series of methylpyrollidine lasofoxifene derivatives that maintained the drug's antagonistic activities while uniquely tuning ERα cellular accumulation. These molecules were examined alongside a panel of antiestrogens in live cell assays of ERα cellular accumulation, lifetime, SUMOylation, and transcriptional antagonism. High-resolution x-ray crystal structures of WT and Y537S ERα ligand binding domain in complex with the methylated lasofoxifene derivatives or representative SERMs and SERDs show that molecules that favor a highly buried helix 12 antagonist conformation achieve the greatest transcriptional suppression activities in breast cancer cells harboring WT/Y537S ESR1 . Together these results show that chemical reduction of ERα cellular lifetime is not necessarily the most crucial parameter for transcriptional antagonism in ESR1 mutated breast cancer cells. Importantly, our studies show how small chemical differences within a scaffold series can provide compounds with similar antagonistic activities, but with greatly different effects of the cellular lifetime of the ERα, which is crucial for achieving desired SERM or SERD profiles.

Nuclear Receptor Modulation – Role of Coregulators in Selective Estrogen Receptor Modulator (SERM) Actions

Molecular Determinants for the Tissue Specificity of SERMs

Selective estrogen receptor modulators: a look ahead

[Effect of selective estrogen receptor modulators on estrogen-sensitive tissues]

Development of Selective Estrogen Receptor Modulator (Serm)-Like Activity Through an Indirect Mechanism of Estrogen Receptor Antagonism: Defining the Binding Mode of 7-Oxabicyclo[2.2.1]hept-5-ene Scaffold Core Ligands.

Advances in Estrogen Receptor Β Coregulator

Recent Advances in Selective Estrogen Receptor Modulators for Breast Cancer

Estrogen Receptor Ligands. Part 10: Chromanes: Old Scaffolds for New SERAMs

Attenuation of Estrogen Receptor Alpha-Mediated Transcription Through Estrogen-Stimulated Recruitment of A Negative Elongation Factor

Benzothiophene Derivatives As Selective Estrogen Receptor Covalent Antagonists: Design, Synthesis and Anti-Erα Activities.

Progress in study of selective ERβ ligands

Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells

Selective Estrogen Receptor Modulators' (SERMs) Influence on TET3 Expression in Breast Cancer Cell Lines with Distinct Biological Subtypes

Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer

Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future

Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer

Rational Design and Optimization of Selenophenes with Basic Side Chains As Novel Potent Selective Estrogen Receptor Modulators (serms) for Breast Cancer Therapy.

Use of SERMs for the adjuvant therapy of early-stage breast cancer

Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development

X-ray Crystallography Study and Optimization of Novel Benzothiophene Analogs As Potent Selective Estrogen Receptor Covalent Antagonists (sercas) with Improved Potency and Safety Profiles.

The immune activity of selective estrogen receptor modulators is gene and macrophage subtype-specific yet converges on Il1b downregulation